Immuneering’s (IMRX) Buy Rating Reiterated at Chardan Capital

Immuneering (NASDAQ:IMRX)‘s stock had its “buy” rating reaffirmed by research analysts at Chardan Capital in a report released on Tuesday,Benzinga reports. They currently have a $13.00 price objective on the stock.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price objective on shares of Immuneering in a research report on Thursday, April 10th.

Immuneering Stock Up 0.8 %

Shares of NASDAQ IMRX opened at $1.25 on Tuesday. The company has a market cap of $44.98 million, a P/E ratio of -0.63 and a beta of -0.22. Immuneering has a 52 week low of $1.00 and a 52 week high of $3.83. The business has a 50-day simple moving average of $1.46 and a two-hundred day simple moving average of $1.81.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). Equities research analysts anticipate that Immuneering will post -1.86 EPS for the current year.

Hedge Funds Weigh In On Immuneering

A number of institutional investors have recently made changes to their positions in IMRX. Tang Capital Management LLC purchased a new position in Immuneering in the fourth quarter worth $27,000. Marshall Wace LLP bought a new stake in Immuneering during the fourth quarter worth about $47,000. First Manhattan CO. LLC. purchased a new position in shares of Immuneering in the 4th quarter worth about $71,000. XTX Topco Ltd increased its position in shares of Immuneering by 177.2% during the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company’s stock valued at $72,000 after purchasing an additional 20,871 shares during the last quarter. Finally, Two Sigma Investments LP raised its holdings in shares of Immuneering by 25.0% during the 4th quarter. Two Sigma Investments LP now owns 50,557 shares of the company’s stock valued at $111,000 after buying an additional 10,126 shares in the last quarter. Institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.